Benzinga's Top Initiations
- Analysts at Baird initiated coverage on Nutanix Inc (NASDAQ: NTNX) with an Outperform rating. The price target for Nutanix is set to $37. Nutanix shares fell 0.77 percent to $30.00 in pre-market trading.
- Analysts at Canaccord Genuity initiated coverage on Hecla Mining Company (NYSE: HL) with a Hold rating. Hecla Mining shares rose 1.39 percent to $5.85 in pre-market trading.
- Analysts at Argus Research initiated coverage of Arista Networks Inc (NYSE: ANET) with a Buy rating. Arista Networks shares fell 0.04 percent to $84.00 in pre-market trading.
- Brean Capital initiated coverage on Logitech International SA (USA) (NASDAQ: LOGI) with a Buy rating. The price target for Logitech is set to $30. Logitech shares slipped 0.79 percent to $21.31 in pre-market trading.
- Analysts at Gabelli & Co. initiated coverage of AAR Corp. (NYSE: AIR) with a Buy rating. AAR shares rose 1.14 percent to close at $31.89 on Monday.
- Analysts at Susquehanna initiated coverage on Hershey Co (NYSE: HSY) with a Neutral rating. Hershey shares declined 0.07 percent to close at $95.29 on Monday.
- Analysts at Citigroup initiated coverage on Calithera Biosciences Inc (NASDAQ: CALA) with a Sell rating. The price target for Calithera Biosciences is set to $1. Calithera Biosciences shares dropped 15.25 percent to $2.50 in pre-market trading.
- Oppenheimer initiated coverage on Nike Inc (NYSE: NKE) with a Perform rating. Nike shares fell 1.47 percent to $51.11 in pre-market trading.
- Analysts at Chardan Capital initiated coverage on Clovis Oncology Inc (NASDAQ: CLVS) with a Sell rating. The price target for Clovis Oncology is set to $15. Clovis Oncology shares fell 7.46 percent to $29.90 in pre-market trading.
- Goldman Sachs initiated coverage on Nutanix Inc (NASDAQ: NTNX) with a Neutral rating. The price target for Nutanix is set to $30. Nutanix shares fell 0.77 percent to $30.00 in pre-market trading.
Latest Ratings for NTNX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2019 | Upgrades | Hold | Buy | |
| Mar 2019 | Downgrades | Outperform | Market Perform | |
| Mar 2019 | Maintains | Outperform | Outperform |
View More Analyst Ratings for NTNX
View the Latest Analyst Ratings
Posted-In: Top InitiationsInitiation Analyst Ratings
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
